You are here: Industry Insights > chronic heart failure

News List

Forxiga Approved in Japan for Chronic Heart Failure americanpharmaceuticalreview
December 16, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving standard of care.
Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint pharmaceutical-business-review
December 20, 2019
Jardiance, a type 2 diabetes drug developed by Boehringer Ingelheim and Eli Lilly and Company (Lilly), failed to meet the primary endpoint of two late-stage exercise ability trials in chronic heart failure.
TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure prnasia
December 17, 2019
Under this IND, TransThera will initiate a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TT-00920 in healthy volunteers. The trial is expected to initiate in early 2020.
FDA Grants Fast Track Designation to Empagliflozin for Chronic Heart Failure americanpharmaceuticalreview
June 28, 2019
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure ...
FDA fast-tracks BI, Lilly's Jardiance in chronic heart failure fiercepharma
June 28, 2019
When Boehringer Ingelheim and Eli Lilly’s diabetes med Jardiance first showed CV benefits in trial patients, it changed the game for the SGLT2 inhibitor class.
Novartis' Entresto helps preserve kidney function in chronic heart failure patients pharmafile
April 17, 2018
Novartis has raised curtains from the 3 phase of clinical trials to protect the kidney function of patients with reduced ejection fraction of heart failure Entresto data.
First dedicated outcome trials of empagliflozin in chronic heart failure initiated lilly
March 20, 2017
EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes